91 – 100 of 115
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Expression of STAT3 in Prostate Cancer Metastases
- Contribution to journal › Article
-
Mark
Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma
- Contribution to journal › Article
-
Mark
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma
- Contribution to journal › Scientific review
-
Mark
Mortality Is Linked to Low Serum Testosterone Levels in Younger and Middle-aged Men
- Contribution to journal › Letter
-
Mark
Serum Testosterone Levels in Early Prediction of Prostate Cancer Risk
- Contribution to journal › Letter
-
Mark
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer : Extended Analysis of the Phase 3 PREVAIL Study
- Contribution to journal › Article
-
Mark
Should we Refrain from Performing Oophorectomy in Conjunction with Radical Cystectomy for Bladder Cancer?
- Contribution to journal › Article
-
Mark
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
- Contribution to journal › Article
-
Mark
Re : Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48-55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder
- Contribution to journal › Debate/Note/Editorial
-
Mark
Re: Treatment Duration of Febrile Urinary Tract Infection: A Pragmatic Randomized, Double-blind, Placebo-controlled Non-inferiority Trial in Men and Women
- Contribution to journal › Debate/Note/Editorial
